Claims

1. Use of a pharmaceutical combination comprising a FGFR4 inhibitor is N-(5-cyano-4-((2- methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4- dihydro-1,8-naphthyridine-1(2H)-carboxamide in citric acid salt form and a bile acid sequestrant in the manufacture of a medicament for reducing or preventing side effects associated with treatment of liver cancer with the FGFR4 inhibitor alone, wherein the side effect does not include diarrhea, wherein the bile acid sequestrant is cholestyramine.

2. Use of a pharmaceutical combination comprising a FGFR4 inhibitor is N-(5-cyano-4-((2- methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4- dihydro-1,8-naphthyridine-1(2H)-carboxamide in citric acid salt form and a bile acid sequestrant in the manufacture of a medicament in the manufacture of a medicament for reducing or preventing an increase of liver enzymes in the serum, plasma or blood of a subject taking FGFR4 inhibitor for the treatment of liver cancer, wherein the bile acid sequestrant is cholestyramine.

3. Use of cholestyramine in the manufacture of a medicament for reducing or preventing side effects associated with treatment of liver cancer with N-(5-cyano-4-((2- methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4- dihydro-1,8-naphthyridine-1(2H)-carboxamide in citric acid salt form wherein the side effect does not include diarrhea.

4. Use of cholestyramine in the manufacture of a medicament for reducing or preventing side effects associated with treatment of liver cancer with N-(5-cyano-4-((2- methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4- dihydro-1,8-naphthyridine-1(2H)-carboxamide in citric acid salt form in a subject, wherein the side effects comprise the increase of liver enzymes in the serum, plasma or blood of the subject.

5. The use according to claim 4, wherein the liver enzyme is alanine aminotransferase (ALT).

6. The use according to claim 4, wherein the side effects comprise the increase of miRNA122.